191 related articles for article (PubMed ID: 18771345)
1. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct.
Kelly MP; Lee FT; Tahtis K; Power BE; Smyth FE; Brechbiel MW; Hudson PJ; Scott AM
Cancer Biother Radiopharm; 2008 Aug; 23(4):411-23. PubMed ID: 18771345
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
3. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice.
Clarke K; Lee FT; Brechbiel MW; Smyth FE; Old LJ; Scott AM
Cancer Res; 2000 Sep; 60(17):4804-11. PubMed ID: 10987290
[TBL] [Abstract][Full Text] [Related]
4. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the targeting characteristics of various radioimmunoconjugates for radioimmunotherapy of neuroblastoma: dosimetry calculations incorporating cross-organ beta doses.
Ugur O; Kostakoglu L; Hui ET; Fisher DR; Garmestani K; Gansow OA; Cheung NK; Larson SM
Nucl Med Biol; 1996 Jan; 23(1):1-8. PubMed ID: 9004907
[TBL] [Abstract][Full Text] [Related]
9. Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor.
Burvenich IJ; Schoonooghe S; Blanckaert P; Bacher K; Vervoort L; Coene E; Mertens N; De Vos F; Slegers G
Nucl Med Biol; 2007 Apr; 34(3):257-65. PubMed ID: 17383575
[TBL] [Abstract][Full Text] [Related]
10. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
Schott ME; Frazier KA; Pollock DK; Verbanac KM
Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
[TBL] [Abstract][Full Text] [Related]
11. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
[TBL] [Abstract][Full Text] [Related]
14. Comparative biodistribution and radioimmunotherapy of monoclonal antibody RS7 and its F(ab')2 in nude mice bearing human tumor xenografts.
Stein R; Blumenthal R; Sharkey RM; Goldenberg DM
Cancer; 1994 Feb; 73(3 Suppl):816-23. PubMed ID: 8306265
[TBL] [Abstract][Full Text] [Related]
15. Biodistribution and tumor localization of 111In-labeled unmodified and modified F(ab')2 fragments of human monoclonal IgM (16.88) in a nude mouse model.
Quadri SM; Siddiqui A; Klein JL; Vriesendorp HM
Nucl Med Biol; 1995 May; 22(4):413-23. PubMed ID: 7550017
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
Yazaki PJ; Wu AM; Tsai SW; Williams LE; Ikler DN; Wong JY; Shively JE; Raubitschek AA
Bioconjug Chem; 2001; 12(2):220-8. PubMed ID: 11312683
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49.
Chauhan SC; Jain M; Moore ED; Wittel UA; Li J; Gwilt PR; Colcher D; Batra SK
Eur J Nucl Med Mol Imaging; 2005 Mar; 32(3):264-73. PubMed ID: 15791435
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Kelly MP; Lee ST; Lee FT; Smyth FE; Davis ID; Brechbiel MW; Scott AM
Prostate; 2009 Jan; 69(1):92-104. PubMed ID: 18942092
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeled F(ab')
Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
[TBL] [Abstract][Full Text] [Related]
20. Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Kelly MP; Lee FT; Tahtis K; Smyth FE; Brechbiel MW; Scott AM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5604s-5612s. PubMed ID: 17875796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
